Clinical Trials Logo

Myelodysplasia clinical trials

View clinical trials related to Myelodysplasia.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05794880 Recruiting - Leukemia Clinical Trials

MCW Alpha/Beta T-Cell and B-Cell Depletion With Targeted ATG Dosing

Start date: May 1, 2023
Phase: N/A
Study type: Interventional

This is a single arm pilot study for patients with hematologic malignancies receiving unrelated or haploidentical related mobilized peripheral stem cells (PSCs) using the CliniMACS system for alpha/beta T cell depletion plus CD19+ B cell depletion with individualized ALC-based dosing of ATG to study impact on engraftment, GVHD, and disease free survival

NCT ID: NCT05735717 Recruiting - Clinical trials for Acute Myeloid Leukemia

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

Start date: May 11, 2023
Phase: Phase 2
Study type: Interventional

This is a phase II, open-label, prospective study of T cell receptor alpha/beta depletion (α/β TCD) peripheral blood stem cell (PBSC) transplantation for children and adults with hematological malignancies

NCT ID: NCT04800458 Recruiting - Thrombocytopenia Clinical Trials

Contribution of Anti-platelet Antibodies Identified With MAIPA Assay in the Demonstration of the Auto-immune Character of a Thrombocytopenia at Diagnosis

APAT
Start date: May 19, 2021
Phase: N/A
Study type: Interventional

Immune thrombocytopenia (ITP) is an autoimmune disease but, paradoxically, and unlike other autoimmune diseases, antiplatelet antibodies are not used either for the diagnosis of the disease or for its prognosis. ITP is a diagnosis of exclusion retained after elimination of other pathologies leading to a thrombocytopenia. No major study has prospectively evaluated the diagnostic value of the presence of anti-platelet antibodies in the etiological investigation of a thrombocytopenia, nor the impact of platelet antibodies on the course of ITP. The gold standard analysis for the determination of platelet antibodies, is the "monoclonal antibody immobilization of platelet antigens" assay (MAIPA), either direct to detect autoantibodies attached to platelets, or indirect to detect circulating antiplatelet antibodies. Therefore, this work aims to study the contribution of the presence of anti-platelet antibodies detected in MAIPA to determine the autoimmune nature of a thrombocytopenia at diagnosis.

NCT ID: NCT04202835 Recruiting - Acute Leukemia Clinical Trials

ATG Plus PTCy vs ATG for CGVHD Prophylaxis

Start date: October 13, 2020
Phase: Phase 2
Study type: Interventional

A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.

NCT ID: NCT03387475 Recruiting - Myelodysplasia Clinical Trials

Evaluating Low-dose Deferasirox (DFX) in Patients With Low-risk MDS Resistant or Relapsing After ESA Agents

LODEFI
Start date: February 20, 2018
Phase: Phase 2
Study type: Interventional

Patients with low-risk MDS verifying the eligibility criteria may be included in the study.

NCT ID: NCT03314974 Recruiting - Multiple Myeloma Clinical Trials

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

Start date: March 30, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II study of allogeneic hematopoietic stem cell transplant (HCT) using a myeloablative preparative regimen (of either total body irradiation (TBI); or, fludarabine/busulfan for patients unable to receive further radiation). followed by a post-transplant graft-versus-host disease (GVHD) prophylaxis regimen of post-transplant cyclophosphamide (PTCy), tacrolimus (Tac), and mycophenolate mofetil (MMF).

NCT ID: NCT02323867 Recruiting - Lymphoma Clinical Trials

Allogeneic Stem Cell Transplant With Alpha/Beta T AND B Cell Depletion for Hematologic Malignancies

AB-CliniMACs
Start date: October 2014
Phase: Phase 2
Study type: Interventional

This is a single arm pilot study for patients using α/β T cell-depleted peripheral Stem Cell Transplantation (PSCT) in with alternative donor sources with hematologic malignancies receiving alternative donor (unrelated or partially matched related) mobilized peripheral stem cells (PSCs) using the CliniMACS system for T cell depletion plus CD19+ B cell depletion to determine efficacy as determined by engraftment and graft versus host disease (GVHD), and one year leukemia free survival.

NCT ID: NCT01962636 Recruiting - Multiple Myeloma Clinical Trials

Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases

Start date: December 2016
Phase: N/A
Study type: Interventional

This is a treatment guideline for an unrelated umbilical cord blood transplant (UCBT) using a myeloablative preparative regimen for the treatment of hematological diseases, including, but not limited to acute leukemias. The myeloablative preparative regimen will consist of cyclophosphamide (CY), fludarabine (FLU) and fractionated total body irradiation (TBI).